Search

Search Constraints

You searched for: Author/Creator Salutari, Vanda

Search Results

1. 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. (20th October 2022)

2. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician's choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). (20th October 2022)

3. A common pattern of somatic mutations in t‐MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer. Issue 11 (8th September 2022)

4. A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters. Issue 9 (October 2015)

5. A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: a multicentric Italian experience. Issue 9 (October 2015)

6. Advanced and recurrent endometrial cancer: State of the art and future perspectives. (December 2022)

7. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. Issue 6 (30th April 2021)

8. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO‐16A/MaNGO‐OV2A study. Issue 6 (June 2021)

9. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. Issue 3 (March 2023)

10. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Issue 2 (February 2021)